Novartis says US regulator grants speedy review of CAR-T cell therapy – Reuters
Forbes |
Novartis says US regulator grants speedy review of CAR–T cell therapy
Reuters The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers. The therapy involves a patient's own T–cells being altered in … Novartis Makes Plans For Its Cancer-Killing T Cells Novartis gets speedy review for CAR–T cell therapy Novartis Says CAR–T Cell Therapy BLA Granted FDA Priority Review |
